Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12625000544471
Ethics application status
Approved
Date submitted
28/04/2025
Date registered
29/05/2025
Date last updated
29/05/2025
Date data sharing statement initially provided
29/05/2025
Type of registration
Prospectively registered
Titles & IDs
Public title
Defining Antibiotic Levels in Intensive care patients 2 (DALI-2) - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients
achieves therapeutic exposures.
Query!
Scientific title
Defining Antibiotic Levels in Intensive care patients 2 (DALI-2) - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients
achieves therapeutic exposures.
Query!
Secondary ID [1]
314303
0
Nil known
Query!
Universal Trial Number (UTN)
U1111-1321-9885
Query!
Trial acronym
DALI-2
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Critical Illness
337249
0
Query!
Serious infection
337248
0
Query!
Condition category
Condition code
Infection
333655
333655
0
0
Query!
Studies of infection and infectious agents
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
False
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
The DALI-2 study does not have a study intervention. Treatment of infection will be conducted according to standard of care by the treating physician. This includes antibiotic dose, frequency, infusion time and duration of therapy and all microbiological cultures. The specific antibiotics includes are (beta-lactams: amoxicillin-clavulanate; amoxicillin; ampicillin; ampicillin/sulbactam; piperacillin-tazobactam; penicillin-G (benzylpenicillin); flucloxacillin; cloxacillin; cephazolin; cefiderocol; cefotaxime; ceftazidime; ceftazidime/avibactam; ceftolozane/tazobactam; ceftriaxone; cefepime; aztreonam; meropenem; imipenem/cilastatin; doripenem; ertapenem; meropenem/vaborbactam; imipenem/cilastin/relebactam; glycopeptides: Vancomycin; teicoplanin, other antibiotics: linezolid; daptomycin; tigecycline; colistin; amikacin; fosfomycin; gentamicin; tobramycin; ciprofloxacin; levofloxacin; trimethoprim/ sulfamethoxazole; metronidazole). Enrolled patients will have two to three blood samples collected over one dosing interval on the selected day of sampling, which is between 24 and 96 hours after starting the study antibiotic. For beta-lactam antibiotics, teicoplanin, and linezolid, two blood samples will be taken, with sample 1 taken mid-way through the dosing interval, and sample 2 taken within 30 minutes of the next dose. For vancomycin, daptomycin, tigecycline, fosfomycin, gentamicin, tobramycin, amikacin, ciprofloxacin, trimethoprim/sulfamethoxazole, and metronidazole, three blood samples will be required to determine the area under of the curve. Sample 1 will be taken 30 minutes after starting the infusion, sample 2 taken mid-way through the dosing interval, and sample 3 taken within 30 minutes of the next dose.
All blood samples will be taken between 24 and 96 hours of antibiotic therapy, At Day 14 after initiation of the study antibiotic, vital status (alive or deceased), and if deceased, was the patient’s death related to infection will be recorded. Emergence of antibiotic resistance is recorded when subsequent cultures collected within 14 days of commencing the study antibiotic identify a resistant organism to the study antibiotic. At Day 30 after initiation of the study antibiotic, vital status (alive or deceased), and if deceased, was the patient’s death related to infection will be recorded. ICU free days at day 30 after initiation of the study antibiotic will be recorded, with deceased patients assigned a penalized value of zero days. Data collection is still required if the patient is transferred from the ICU to the ward or discharged.
Query!
Intervention code [1]
330917
0
Not applicable
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
341240
0
Number of critically ill patients who achieve pre-defined therapeutic antibiotic exposures (concentrations)
Query!
Assessment method [1]
341240
0
Up to three blood samples collected over one dosing interval on the selected day of sampling, These samples will be used to determine the unbound or total plasma antibiotic concentration and used to determine the achievement of pre-defined therapeutic antibiotics exposures. Pre-defined therapeutic exposures/concentration include: BETA-LACTAMS - Amoxicillin/ampicillin, benzylpenicillin, cloxacillin, cefiderocol, cefotaxime, ceftazidime, cephazolin (100%fT at or above the MIC to 50 mg/L); flucloxacillin, (100%fT at or above the MIC to 10 mg/L); piperacillin, (100%fT at or above the MIC to 130 mg/L); cefepime (100%fT at or above the MIC to 28 mg/L); ceftriaxone, (100%fT at or above the MIC to 89 mg/L); doripenem (100%fT at or above the MIC to 20 mg/L); ertepenem, (100%fT at or above the MIC to 10 mg/L); imipenem, (100%fT at or above the MIC to 40 mg/L); meropenem, (100%fT at or above the MIC to 44 mg/L); aztreonam, (100%fT at or above the MIC to 80 mg/L); avibactam, at or above 50%fT above 1mg/L; clavulanate, at or above 20%fT above 1mg/L; relebactam, fAUC0-24/MIC at or above 5.2; sulbactam, at or above 60%fT at or above the MIC; tazobactam, trough between 5mg/L and 20mg/L; vaborbactam, fAUC0-24/MIC above 24; GLYCOPEPTIDES - vancomycin, AUC0-24/MIC 400 to an AUC0-24 700 mg*h/L ; teicoplanin, trough 15 mg/l to 50 mg/L; OTHERS - amikacin, Cmax/MIC at or above 8 to a trough of 2.5 mg/L; gentamicin/tobramycin, Cmax/MIC at or above 8 to a trough of 0.5 mg/L; colistin, Css,avg at or above 2 mg/L to a trough of 3 mg/L; daptomycin, AUC0-24/MIC at or above 666 to a trough of 24 mg/L; fluoroquinolones, fAUC0-24/MIC at or above 100 to fAUC0-24 equal to 500 mg*h/L; fosfomycin, AUC0-24/MIC at or above 83 mg to a Cmax of 577 mg/L; linezolid, trough 2 mg/L to 7 mg/L; trimethoprim/sulfamethoxazole, trimethoprim Cmax at or above 5 mg/L to a trough of 8 mg/L; tigecycline, AUC0-24/MIC at or above 4.5 to an AUC0-24 equal to 20.76 mg*h/L. For BETA-LACTAMS, teicoplanin and linezolid, two blood samples are required, with sample 1 taken mid-way through the dosing interval, and sample 2 taken within 30 minutes of the next dose. For vancomycin, daptomycin, tigecycline, fosfomycin, gentamicin, tobramycin, amikacin, ciprofloxacin, trimethoprim/sulfamethoxazole, and metronidazole, three blood samples are required with samples one taken 30 minutes after starting the infusion, sample 2 taken midway through the same dosing interval, and sample 3 taken within 3o minutes of the next dose.
Query!
Timepoint [1]
341240
0
During one dosing interval between 24 and 96 hours after starting study antibiotic.
Query!
Secondary outcome [1]
447313
0
In adults administered vancomycin, the number of participants who achieve a trough concentration of 15 mg/L or greater when administered via intermittent infusion.
Query!
Assessment method [1]
447313
0
Three blood samples collected over one dosing interval on the selected day of sampling, These samples will be used to determine the total plasma vancomycin concentration.
Query!
Timepoint [1]
447313
0
During one dosing interval between 24 and 96 hours after starting study antibiotic.
Query!
Secondary outcome [2]
447314
0
In children administered vancomycin, the number of participants achieving a trough concentration range of 15 to 20 mg/L for methicillin-resistant Staphylococcus aureus (MRSA)
Query!
Assessment method [2]
447314
0
Three blood samples collected over one dosing interval on the selected day of sampling, These samples will be used to determine the total plasma vancomycin concentration.
Query!
Timepoint [2]
447314
0
During one dosing interval between 24 and 96 hours after starting study antibiotic.
Query!
Secondary outcome [3]
446894
0
Number of participants with a positive clinical outcome.
Query!
Assessment method [3]
446894
0
Positive clinical outcome is defined as completion of treatment course, or de-escalation without new antibiotic therapy for same indication within 48-hours of cessation. Positive clinical outcome data will be collected from medical records.
Query!
Timepoint [3]
446894
0
Positive clinical outcome - 48 hours after cessation of antibiotic
Query!
Secondary outcome [4]
447324
0
Infection related mortality
Query!
Assessment method [4]
447324
0
At day 14 and day 30 after initiation of the study antibiotic, vital status will be determined (alive or deceased). This assessment will be made from data collected from medical records or for study participants who have been discharged from hospital, this assessment will be made by contacting the participant via phone at day 14 and day30 after initiation of the study antibiotic. If deceased, an assessment as to whether the patient’s death was related to infection will be made, as per the treating team's assessment.
Query!
Timepoint [4]
447324
0
Mortality - day 14 and day 30 after initiation of the study antibiotic
Query!
Secondary outcome [5]
447325
0
ICU free days at day 30 after initiation of the study antibiotic.
Query!
Assessment method [5]
447325
0
ICU free days at day 30 after initiation of the study antibiotic will be recorded, with deceased patients assigned a penalized value of zero days. This assessment will be made from data collected from medical records
Query!
Timepoint [5]
447325
0
at day 30 after initiation of the study antibiotic.
Query!
Secondary outcome [6]
446893
0
Number of critically ill patients who achieve beta-lactam exposures of: 50% free time at or above the MIC,
Query!
Assessment method [6]
446893
0
two blood samples collected over one dosing interval on the selected day of sampling, These samples will be used to determine the unbound plasma antibiotic concentration and used to determine the achievement of the beta-lactam exposure target.
Query!
Timepoint [6]
446893
0
During one dosing interval between 24 and 96 hours after starting study antibiotic.
Query!
Secondary outcome [7]
446897
0
Pharmacokinetics of antibiotics (e.g. volume of distribution, and clearance)
Query!
Assessment method [7]
446897
0
Using blood samples, WinNonlin will be used to fit a noncompartmental model to the data to describe an individual's pharmacokinetics for specific antibiotics.
Query!
Timepoint [7]
446897
0
All blood samples collected during one dosing interval between 24 and 96 hours of antibiotic therapy will be used to assess the pharmacokinetics of antibiotics. For BETA-LACTAMS, teicoplanin and linezolid, two blood samples are required, with sample 1 taken mid-way through the dosing interval, and sample 2 taken within 30 minutes of the next dose. For vancomycin, daptomycin, tigecycline, fosfomycin, gentamicin, tobramycin, amikacin, ciprofloxacin, trimethoprim/sulfamethoxazole, and metronidazole, three blood samples are required with samples one taken 30 minutes after starting the infusion, sample 2 taken midway through the same dosing interval, and sample 3 taken within 3o minutes of the next dose.
Query!
Secondary outcome [8]
446895
0
Number of participants who surpass the pre-defined values associated with toxicity
Query!
Assessment method [8]
446895
0
Up to three blood samples collected over one dosing interval on the selected day of sampling, These samples will be used to determine the unbound or total plasma antibiotic concentration and used to determine the achievement of pre-defined exposures associated with toxicity. Toxicity exposures are those concentration that exceed the therapeutic exposures upper value. Pre-defined therapeutic exposures/concentration include: Amoxicillin/ampicillin, benzylpenicillin, cloxacillin, cefiderocol, cefotaxime, ceftazidime, cephazolin (100%fT at or above the MIC to 50 mg/L); flucloxacillin, (100%fT at or above the MIC to 10 mg/L); piperacillin, (100%fT at or above the MIC to 130 mg/L); cefepime (100%fT at or above the MIC to 28 mg/L); ceftriaxone, (100%fT at or above the MIC to 89 mg/L); doripenem (100%fT at or above the MIC to 20 mg/L); ertepenem, (100%fT at or above the MIC to 10 mg/L); imipenem, (100%fT at or above the MIC to 40 mg/L); meropenem, (100%fT at or above the MIC to 44 mg/L); aztreonam, (100%fT at or above the MIC to 80 mg/L); avibactam, at or above 50%fT above 1mg/L; clavulanate, at or above 20%fT above 1mg/L; relebactam, fAUC0-24/MIC at or above 5.2; sulbactam, at or above 60%fT at or above the MIC; tazobactam, trough between 5mg/L and 20mg/L; vaborbactam, fAUC0-24/MIC above 24; vancomycin, AUC0-24/MIC 400 to an AUC0-24 700 mg*h/L ; teicoplanin, trough 15 mg/l to 50 mg/L; amikacin, Cmax/MIC at or above 8 to a trough of 2.5 mg/L; gentamicin/tobramycin, Cmax/MIC at or above 8 to a trough of 0.5 mg/L; colistin, Css,avg at or above 2 mg/L to a trough of 3 mg/L; daptomycin, AUC0-24/MIC at or above 666 to a trough of 24 mg/L; fluoroquinolones, fAUC0-24/MIC at or above 100 to fAUC0-24 equal to 500 mg*h/L; fosfomycin, AUC0-24/MIC at or above 83 mg to a Cmax of 577 mg/L; linezolid, trough 2 mg/L to 7 mg/L; trimethoprim/sulfamethoxazole, trimethoprim Cmax at or above 5 mg/L to a trough of 8 mg/L; tigecycline, AUC0-24/MIC at or above 4.5 to an AUC0-24 equal to 20.76 mg*h/L. For some antibiotics, the toxicity value is unknown and they will be excluded from this outcome measure.
Query!
Timepoint [8]
446895
0
During one dosing interval between 24 and 96 hours after starting study antibiotic.
Query!
Secondary outcome [9]
447315
0
In children administered vancomycin, the number of participants achieving a trough concentration range of 10 to 15 mg/L for non- methicillin-resistant Staphylococcus aureus (MRSA)
Query!
Assessment method [9]
447315
0
Three blood samples collected over one dosing interval on the selected day of sampling, These samples will be used to determine the total plasma vancomycin concentration.
Query!
Timepoint [9]
447315
0
During one dosing interval between 24 and 96 hours after starting study antibiotic.
Query!
Secondary outcome [10]
447320
0
Number of critically ill patients who achieve beta-lactam exposures of 100% free time at or above MIC
Query!
Assessment method [10]
447320
0
two blood samples collected over one dosing interval on the selected day of sampling, These samples will be used to determine the unbound plasma antibiotic concentration and used to determine the achievement of the beta-lactam exposure target.
Query!
Timepoint [10]
447320
0
During one dosing interval between 24 and 96 hours after starting study antibiotic.
Query!
Secondary outcome [11]
446898
0
To systematically evaluate the feasibility for implementation of the DALI-2 study across intensive care units globally.
Query!
Assessment method [11]
446898
0
A mixed-methods approach will be used to evaluate the feasibility for implementation of the study across ICUs globally. The questionnaires used will be designed specifically for this study. The site investigators and research coordinators will be the respondents to questionnaires to assess this outcome. This assessment will include a thematic approach to identify common themes regarding barriers and facilitators to implementation.
Query!
Timepoint [11]
446898
0
Feasibility assessed at the conclusion of the study at each site.
Query!
Secondary outcome [12]
447323
0
Number of participants with a Negative clinical outcome.
Query!
Assessment method [12]
447323
0
Those who do not achieve a positive clinical outcome: defined as completion of treatment course, or de-escalation without new antibiotic therapy for same indication within 48-hours of cessation. This assessment will be made from data collected from medical records.
Query!
Timepoint [12]
447323
0
Negative clinical outcome - 48 hours after cessation of antibiotic
Query!
Secondary outcome [13]
447319
0
Number of critically ill patients who achieve beta-lactam exposures of 50% free time at or above 4 times the MIC,
Query!
Assessment method [13]
447319
0
two blood samples collected over one dosing interval on the selected day of sampling, These samples will be used to determine the unbound plasma antibiotic concentration and used to determine the achievement of the beta-lactam exposure target.
Query!
Timepoint [13]
447319
0
During one dosing interval between 24 and 96 hours after starting study antibiotic.
Query!
Secondary outcome [14]
447321
0
Number of critically ill patients who achieve beta-lactam exposures of 100% free time at or above 4 times the MIC.
Query!
Assessment method [14]
447321
0
two blood samples collected over one dosing interval on the selected day of sampling, These samples will be used to determine the unbound plasma antibiotic concentration and used to determine the achievement of the beta-lactam exposure target.
Query!
Timepoint [14]
447321
0
During one dosing interval between 24 and 96 hours after starting study antibiotic.
Query!
Secondary outcome [15]
446896
0
Adverse drug events
Query!
Assessment method [15]
446896
0
A suspected adverse drug event is defined as an event that occurs after the administration of a study antibiotic AND the treating physician suspects the event was caused by the study antibiotic. Suspected adverse events is a composite outcome and will be categorised as either: a) Neurotoxicity: documented seizure activity b) Nephrotoxicity: an increased serum creatinine x 1.5 or more, or estimated glomerular filtration rate decrease of greater than 25% or urine output less than 0.5 mL/kg/hr over 6 hours c) Hepatotoxicity: liver function test ratios according to the Roussel Uclaf Causality Assessment Method d) Hematological toxicity: thrombocytopenia (platelet count less than 50 x 109/L) or neutropenia (neutrophil count of 0.5 x 109/L or less)
Query!
Timepoint [15]
446896
0
During the antibiotic course and followed up for 48-hours post-antibiotic cessation.
Query!
Secondary outcome [16]
447365
0
To systematically evaluate the site readiness for implementation of the DALI-2 study across intensive care units globally.
Query!
Assessment method [16]
447365
0
A mixed-methods approach will be used to evaluate the site readiness for implementation of the study across ICUs globally. The questionnaires used will be designed specifically for this study. The site investigators and research coordinators will be the respondents to questionnaires to assess this outcome. This assessment will include a thematic approach to identify common themes regarding barriers and facilitators to implementation.
Query!
Timepoint [16]
447365
0
Site readiness assessed at the conclusion of the study at each site.
Query!
Secondary outcome [17]
447326
0
Emergence of antibiotic resistance
Query!
Assessment method [17]
447326
0
Emergence of antibiotic resistance is recorded when subsequent microbiological cultures (e.g. blood, deep fluid or pus, deep tissue, sputum and urine) collected within 14 days of commencing the study antibiotic identify a resistant organism to the study antibiotic. This assessment will be made from data collected from medical records.
Query!
Timepoint [17]
447326
0
Emergence of antibiotic resistance - at day 14
Query!
Secondary outcome [18]
447318
0
In adults administered vancomycin, the number of participants who achieve a steady state concentration of 15 to 25 mg/L when administered as a continuous infusions.
Query!
Assessment method [18]
447318
0
Three blood samples collected over one dosing interval on the selected day of sampling, These samples will be used to determine the total plasma vancomycin concentration.
Query!
Timepoint [18]
447318
0
During one dosing interval between 24 and 96 hours after starting study antibiotic.
Query!
Eligibility
Key inclusion criteria
Patients are eligible for inclusion in the DALI-2 study if all the following inclusion criteria are met:
1. Patient is admitted to an ICU.
2. Patient receiving one of the specified intravenous antibiotics (including beta-lactams, glycopeptides, aminoglycosides and others) for the treatment of infection (i).
3. Suitable intravenous/intra-arterial access to facilitate sample collection. Capillary samples can be used in children if required. (arterial line preferred for sample collection).
4. Corrected gestational age of patient of 1 month or greater.
5. The patient must have been administered the study antibiotic for at least 24 hours.
(i). Treatment is defined as either: empiric therapy (a clinical syndrome that may be due to infection is being treated) e.g. empiric antibiotics for aspiration pneumonitis/pneumonia, or directed therapy (treating an infection where a causative organism is identified). Please note that post-operative prophylactic antibiotics are not included.
Query!
Minimum age
1
Months
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Patient’s death is deemed imminent and inevitable.
2. Patients who have received the study antibiotic for a duration exceeding 96 hours without accompanying blood sample collection.
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/07/2025
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
30/06/2027
Query!
Actual
Query!
Date of last data collection
Anticipated
31/07/2027
Query!
Actual
Query!
Sample size
Target
1250
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,NT,QLD,SA,WA,VIC
Query!
Recruitment outside Australia
Country [1]
27013
0
Taiwan, Province Of China
Query!
State/province [1]
27013
0
Query!
Country [2]
27012
0
United Kingdom
Query!
State/province [2]
27012
0
Query!
Country [3]
27017
0
Spain
Query!
State/province [3]
27017
0
Query!
Country [4]
27010
0
China
Query!
State/province [4]
27010
0
Query!
Country [5]
27019
0
Turkey
Query!
State/province [5]
27019
0
Query!
Country [6]
27015
0
Greece
Query!
State/province [6]
27015
0
Query!
Country [7]
27009
0
New Zealand
Query!
State/province [7]
27009
0
Query!
Country [8]
27014
0
Belgium
Query!
State/province [8]
27014
0
Query!
Country [9]
27011
0
France
Query!
State/province [9]
27011
0
Query!
Country [10]
27018
0
Portugal
Query!
State/province [10]
27018
0
Query!
Country [11]
27016
0
Sweden
Query!
State/province [11]
27016
0
Query!
Funding & Sponsors
Funding source category [1]
318933
0
Government body
Query!
Name [1]
318933
0
NHMRC Investigator Grant (APP2009736)
Query!
Address [1]
318933
0
Query!
Country [1]
318933
0
Australia
Query!
Funding source category [2]
318826
0
Government body
Query!
Name [2]
318826
0
Australian National Health and Medical Research Council (NHMRC) Centre of Research Excellence RESPOND (APP2007007)
Query!
Address [2]
318826
0
Query!
Country [2]
318826
0
Australia
Query!
Primary sponsor type
University
Query!
Name
University of Queensland
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
321272
0
Hospital
Query!
Name [1]
321272
0
CHU Nimes
Query!
Address [1]
321272
0
Query!
Country [1]
321272
0
France
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
317441
0
Children’s Health Queensland Hospital and Health Service Human Research Ethics Committee
Query!
Ethics committee address [1]
317441
0
http://www.childrens.health.qld.gov.au/research/human-research-ethics-committee
Query!
Ethics committee country [1]
317441
0
Australia
Query!
Date submitted for ethics approval [1]
317441
0
06/09/2024
Query!
Approval date [1]
317441
0
12/02/2025
Query!
Ethics approval number [1]
317441
0
HREC/2024/QCHQ/111399
Query!
Summary
Brief summary
The primary purpose of the DALI-2 study is to describe the achievement of therapeutic antibiotic exposures (concentrations) in critically ill patients. Our HYPOTHESIS is that failing to achieve therapeutic antibiotic exposures (concentrations) in critically ill patients is an independent determinant of clinical outcomes, including clinical failure, mortality, ICU-free days, and the emergence of antimicrobial resistance, across diverse patient populations. Our VISION for DALI-2 is to pioneer a new era in the management of severe infections by providing definitive evidence that will reshape antibiotic dosing strategies for critically ill patients globally, irrespective of age. We aim to set a new benchmark for treatment efficacy and safety.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Pre-defined exposures determined by either expert consensus opinion and the following references: 1. Sy SKB, Zhuang L, Sy S, Derendorf H. Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime–Avibactam Combination: A Model-Informed Strategy for its Clinical Development. Clinical pharmacokinetics. 2019;58(5):545-64. 2. Monogue ML, Nicolau DP. Pharmacokinetics-pharmacodynamics of ß-lactamase inhibitors: are we missing the target? Expert Review of Anti-infective Therapy. 2019;17(8):571-82. 3. Roberts JA, Joynt GM, Lee A, Choi G, Bellomo R, Kanji S, et al. The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data from the Multinational Sampling Antibiotics in Renal Replacement Therapy Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021;72(8):1369-78. 4. Gatti M, Rinaldi M, Gaibani P, Siniscalchi A, Tonetti T, Viale P, et al. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in the treatment of critically ill patients with documented KPC-producing Klebsiella pneumoniae ventilator-associated pneumonia. International Journal of Antimicrobial Agents. 2023;62(5):106992. 5. Child J, Chen X, Mistry RD, Somme S, MacBrayne C, Anderson PL, et al. Pharmacokinetic and Pharmacodynamic Properties of Metronidazole in Pediatric Patients With Acute Appendicitis: A Prospective Study. Journal of the Pediatric Infectious Diseases Society. 2018;8(4):297-302. 6. Lau WK, Young LS. Trimethoprim-sulfamethoxazole treatment of Pneumocystis carinii pneumonia in adults. The New England journal of medicine. 1976;295(13):716-8. 7. Yang X, Jin L, Luo X, An S, Wang M, Zhu H, et al. Pharmacokinetic/Pharmacodynamic Target Attainment of Tigecycline in Patients with Hepatic Impairment in a Real-World Setting. Ther Drug Monit. 2023;45(6):786-91. 8. Yang X, Jin L, Luo X, Wang M, Zhu H, Zhou Y, et al. Serum concentration as a predictor of tigecycline-induced hypofibrinogenemia in critically ill patients: A retrospective cohort study. International Journal of Infectious Diseases. 2022;123:136-42. 9. Abdul-Aziz MH, Alffenaar J-WC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#. Intensive Care Medicine. 2020;46(6):1127-53.
Query!
Contacts
Principal investigator
Name
141038
0
Prof Jason Roberts
Query!
Address
141038
0
UQ Centre for Clinical Research, Level 8, UQCCR building 71/918 RBWH Campus, Herston QLD 4029
Query!
Country
141038
0
Australia
Query!
Phone
141038
0
+61 7 3346 5032
Query!
Fax
141038
0
Query!
Email
141038
0
[email protected]
Query!
Contact person for public queries
Name
141039
0
Paul Williams
Query!
Address
141039
0
UQ Centre for Clinical Research, Level 8, UQCCR building 71/918 RBWH Campus, Herston QLD 4029
Query!
Country
141039
0
Australia
Query!
Phone
141039
0
+61 7 3346 5032
Query!
Fax
141039
0
Query!
Email
141039
0
[email protected]
Query!
Contact person for scientific queries
Name
141040
0
Paul Williams
Query!
Address
141040
0
UQ Centre for Clinical Research, Level 8, UQCCR building 71/918 RBWH Campus, Herston QLD 4029
Query!
Country
141040
0
Australia
Query!
Phone
141040
0
+61 7 3346 5032
Query!
Fax
141040
0
Query!
Email
141040
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
No
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF